Vaccination News Home Page

http://www.blackwell-synergy.com/servlet/useragent?func=synergy&synergyAction=showAbstract&doi=10.1046/j.1442-200X.2002.01606.x

Abstract
 

Pediatrics International
Volume 44 Issue 5 Page 510  - October 2002

 
Original Article
Prevalence of Mycoplasma pneumoniae in children in Diyarbakir, the south-east of Turkey
Mehmet Bosnak,1 Bunyamin Dikici,1 Vuslat Bosnak,2 Omer Dogru,1 Ilker Ozkan,1 Ali Ceylan3 and Kenan Haspolat1
 
 Abstract

Background: Mycoplasma pneumoniae is a well known causative agent of infection in childhood but clinical presentation may be variable. History and physical examination may not be so helpful for the diagnosis. It is difficult to culture this infectious agent, with the culture technique for the multiplication of the organism for routine investigation hard to obtain. The determination of exposure and prevalence of the disease of any region should be helpful for clinical diagnosis. In this study, we aimed to determine the seroprevalence of M. pneumoniae in children aged 0-14 years in Diyarbakir and establish the distribution of infection prevalence of various age groups of children.

Methods: Thirty streets were determined according to the cluster method for the 0-6 years age group. In this age group, a total of 180 blood samples were collected; so that there were 30 samples for each age. For children aged 7-14 years, elementary school children were selected. There were 70 elementary schools in the city and 14 schools were randomly selected according to the randomized numbers table with a 20% sample. Finally, 276 blood samples were collected. Mycoplasma pneumoniae was determined by using the enzyme immunoassay method. For this method MELOTEST Mycoplasma IgG reagent was used.

Results: The highest seropositivity rate was encountered at 10 years of age (65%) and lowest was at 2 years of age (0%). The overall M. pneumoniae seropositivity was 27% when all ages were considered together. The first 2 years of age excluded this rate and was 31.9%. A sudden increase of seropositivity was observed at 7 years of age.

Conclusions: Increasing seroprevalence rates of M. pneumoniae after 2 years of age should alert clinicians to consider the organism in the differential diagnosis of infectious diseases in this age group. The low seroprevalence rates in the first 2 years of age was thought to be due to low risk of community-based spread of the organism in this age group. The most prominent increase in seroprevalence was at 10 years of age. This data indicated that M. pneumoniae should be kept in mind while making differential diagnosis of infections. The spreading of disease and community-based transmission is also important to consider. In our study, seroprevalence rates increased at 6 and 7 years of age, at the beginning of the school age as community-based transmission takes place most commonly in crowded circumstances. In conclusion, M. pneumoniae should be thought as an important infectious agent in childhood for all age groups.

 
Access Full Article HTML    Access Full Article PDF
 
List of Issues
image
Table of Contents
image
Previous Article Next Article
image
Add to Favorites
image
Email to a Friend
image
Jacket

for
Authors:
Mehmet Bosnak,
Bunyamin Dikici,
Vuslat Bosnak,
Omer Dogru,
Ilker Ozkan,
Ali Ceylan
Kenan Haspolat
child
Mycoplasma pneumoniae
prevalence

 

Departments of 1Pediatrics, 2Infectious Diseases and 3Public Health, Dicle University Medical School, Diyarbakir, Turkey

 
Correspondence: Mehmet Bosnak MD, Dicle Universitesi, Tip Fakultesi, Cocuk Sagligi ve Hastaliklari Anabilim Dali, Diyarbakir, Turkey. Email: mbosnak@dicle.edu.tr
To cite this article
Bosnak, Mehmet, Dikici, Bunyamin, Bosnak, Vuslat, Dogru, Omer, Ozkan, Ilker, Ceylan, Ali & Haspolat, Kenan
Prevalence of Mycoplasma pneumoniae in children in Diyarbakir, the south-east of Turkey.
Pediatrics International 44 (5), 510-512.
doi: 10.1046/
j.1442-200X.2002.01606.x

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.